Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Brenner Tumor 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Lymphoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 18Carboplatin 16Taxes 12Cisplatin 7Bevacizumab 7Immunoglobulin G 4Disulfides 4Topotecan 3VTX-2337 2SS1(dsFv)PE38 2Platinum 2Filgrastim 2Erlotinib Hydrochloride 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1paclitaxel poliglumex 1liposomal doxorubicin 1elesclomol 1belinostat 1Thiotepa 1Reverse Transcriptase Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Mental Status and Dementia Tests 1Melphalan 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Brenner Tumor × VTX-2337 × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

NCT01294293 2014-12-25

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

GOG Foundation

Phase 1 Completed
20 enrolled
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡